Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World November 14, 2008 Hepeng Jia	Traditional Chinese medicine firm struggles for approval HSR has spent the past eight years developing Fufang Sanhuangsan, which contains compounds derived from several plants including skullcap, dandelion and bupleurum.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
American Family Physician January 15, 2006 Ann M. Khalsa	Preventive Counseling, Screening, and Therapy for the Patient with Newly Diagnosed HIV Infection The epidemic of HIV continues, and the infection is converting into a treatable chronic disease; therefore, it is increasingly important for family physicians to be current with and comfortable in providing basic care to patients infected with HIV.
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
The Motley Fool July 10, 2006 Brian Lawler	Northfield Frowns on Focus From "20/20" The maker of artificial blood finds yet another critic. But the impending end of the PolyHeme trial probably won't represent the end of criticism of the artificial blood. Only if good clinical trial results are announced later this year will Northfield's critics be silenced.
American Family Physician October 15, 2000 Todd A. May, Cristina I. Gruta & Ronald H. Goldschmidt	Letters to the Editor For the family physician caring for HIV-infected patients who are responders to potent combination antiretroviral therapy, omitting primary PCP prophylaxis while carefully monitoring for any signs of disease progression is a reasonable management strategy...
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
Nursing January 2011 Carl A. Kirton	HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
American Family Physician August 1, 2000 Sharon Scott Morey	Practice Guidelines HHS Updates Guidelines for Antiretroviral Therapy in HIV Infection
Chemistry World March 10, 2008 Victoria Gill	New Hope for Anti-HIV Gels Early data from a clinical trial has rekindled hope of an effective topical gel to prevent HIV infection.
Chemistry World July 17, 2012 Andrew Turley	First HIV drug approved as prevention US regulators have for the first time approved a drug to be used to prevent HIV infection -- as opposed to treating it.
American Family Physician February 1, 2001 Eleftherios Mylonakis	Plasma Viral Load Testing in the Management of HIV Infection In the 1990s, new technologies, including the polymerase chain reaction assay, the branched DNA assay and the nucleic acid sequence-based amplification assay, made it possible to obtain accurate quantitative measurements of human immunodeficiency virus (HIV) RNA in plasma...
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool May 17, 2010 Luke Timmerman	Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir.
BusinessWeek October 20, 2003 Gene G. Marcial	How Immune Response Targets AIDS Immune Response's Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. A look at the company's situation and its stock.
Fast Company December 2009 Elizabeth Svoboda	Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas.
American Family Physician January 1, 2001 Alex H. Krist	Obstetric Care in Patients with HIV Disease Appropriate management of pregnant patients who have human immunodeficiency virus (HIV) disease can have a major impact on maternal and infant health...
The Motley Fool September 13, 2007 Brian Orelli	Alfacell's Awkward Wait Waiting for subjects to die is a somber part of the oncology clinical trial process. Alfacell is doing just that in its final phase three trial with its lead cancer drug candidate. Investors take note.
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
Chemistry World July 25, 2006 Bea Perks	Clinical Chaos Under Scrutiny Clinical trials of new drugs need to be tightened up, according to an expert group convened in the aftermath of UK trials that left six people fighting for their lives.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
Chemistry World August 4, 2008 Pete Mitchell	Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
The Motley Fool November 29, 2010 Brian Orelli	Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.
The Motley Fool May 31, 2011 Brian Orelli	5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals.
Salon.com July 17, 2000 Nina Teicholz	When drugs take a holiday Could taking a break from protease inhibitors be the secret to treating AIDS? A new case of a 40-year-old man in Philadelphia shows it's possible.
Chemistry World September 26, 2007 Victoria Gill	HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed.
Chemistry World April 2006 Karen Harries-Rees	Editorial: Drugs Testing on Trial A drugs trial in the UK that went disastrously wrong last month has raised questions about the ethics of using paid volunteers in clinical trials and the usefulness of animal testing.
The Motley Fool September 14, 2009 Brian Orelli	More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
BusinessWeek April 30, 2007 Catherine Arnst	Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
BusinessWeek November 24, 2003 John Carey	Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
Pharmaceutical Executive July 1, 2006 Derek Lowe	What You Need to Know About Adaptive Trials A handful of new statistical techniques and clinical-trial designs will let you change the way you run your business. Here's your guide to the basics.
Chemistry World February 9, 2007 Victoria Gill	Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo.
Pharmaceutical Executive February 1, 2007 John Smith	Public Relations: Beef Up Clinical Trial Numbers Web-based public relations can make the difference in clinical-trial recruitment.
The Motley Fool June 23, 2009 Brian Orelli	Wonder Drug! Maybe? Get the facts before jumping on this one.
The Motley Fool September 7, 2007 Brian Orelli	Clinical Data Gets Personal Clinical Data's lead compound Vilazodone posts strong phase 3 results. The company is searching for common genetic markers among patients who responded positively to the drug.
Chemistry World February 26, 2014 Ned Stafford	Roche disputes unethical East German trial claims Clinical trials in the 1980s, performed in former communist East Germany by global pharmaceutical giant Hoffmann-La Roche, adhered to international standards and did not violate East German laws, according to a report issued by the company after a six month internal investigation.
American Family Physician July 15, 2004 Joel E. Gallant	HIV Counseling, Testing, and Referral By the year 2005, the CDC seeks to achieve the following: reduce annual new HIV infections from the current estimated 40,000 cases to 20,000 cases through the use of interventions such as counseling, HIV testing, and referral
Bio-IT World April 16, 2004 Mark Uehling	PDAs and Clinical Trials PalmOne's director of healthcare sales explains why clinical trials are driving sales of handheld devices.
American Family Physician December 1, 2000 William E. Chavey	The Importance of Beta Blockers in the Treatment of Heart Failure Traditionally, beta blockers have been considered to be contraindicated in patients with heart failure. Recently, however, several large randomized, controlled mortality trials have been stopped early because of the effects of beta blockers...
Chemistry World April 27, 2007 Ned Stafford	New HIV Blocker Prepares for Trials Scientists who isolated a natural component of human blood that defends against the HIV-1 virus are now moving quickly to test their ideas clinically in the hope of bringing a new class of HIV-blockers based on peptide therapeutics to market.